News | April 30, 2021
Indian vaccine players to garner Rs. 70,599 Cr in 2021
Riding COVID-19 wave, Indian vaccine industry set to be Rs. 700 billion strong
Riding COVID-19 wave, Indian vaccine industry set to be Rs. 700 billion strong
Molnupiravir is an investigational oral antiviral drug currently being studied in a Phase 3 trial for the treatment of non-hospitalized patients with confirmed COVID-19
This achievement enables the company to strengthen its presence in the high growth market of South Asian countries
In animal health, the products will be mainly targeting mastitis and production disorders, gastrointestinal tract diseases, reproductive disorders, ectoparasites, and skin injuries
Lonza's Ibex Design end-to-end offering will cover the development stages of IMT-009 from development candidates through early clinical studies
Acquisition of A&C expands Aceto’s Western manufacturing footprint
Presently, IMPCL is manufacturing 656 classical Ayurvedic, 332 Unani and 71 proprietary Ayurvedic medicines for the various diseases spectrum
The merger is in line with Solara’s strategy of accelerating growth via appropriate inorganic actions
Both the vaccines have been extensively tested by IVRI for safety and potency and have been found to provide 100% protection
The government has taken all the effective measures to make healthcare affordable
Subscribe To Our Newsletter & Stay Updated
